The Federal Aviation Administration permits pilots to hold valid medical certificates while taking certain antidepressant medications, provided they obtain authorization through the Special Issuance process — a case-by-case medical review distinct from standard medical certification. The FAA currently recognizes eight approved medications under this pathway: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram (Celexa), duloxetine (Cymbalta), venlafaxine (Effexor), desvenlafaxine (Pristiq), and bupropion in both its sustained-release and extended-release formulations (Wellbutrin SR and ER). Pilots seeking Special Issuance must work directly with an Aviation Medical Examiner and submit specific evaluations and documentation, the requirements for which the FAA has publicly published to eliminate ambiguity about expectations.
The practical and legal stakes of this issue are significant for any certificated pilot. Falsifying or omitting mental health treatment information on an FAA Form 8500-8 — the medical application — constitutes a federal offense under 18 U.S.C. § 1001 and can result in certificate revocation, civil penalties, and criminal prosecution. Historically, the stigma surrounding mental health treatment in aviation led many pilots to avoid seeking care or to conceal treatment from the FAA, creating both a safety risk and a legal liability. The FAA's expansion of the approved antidepressant list and its transparent publication of Special Issuance requirements represent a deliberate effort to reduce that concealment incentive by making the path to legal certification achievable and clearly defined.
For airline pilots operating under Part 121, the Special Issuance process carries additional complexity because First Class medical standards apply and must be renewed every six months for pilots under age 40 and annually thereafter. Corporate and business aviation pilots operating under Part 91, 91K, or Part 135 typically hold Second or Third Class certificates, though Part 135 operators conducting for-hire operations require at minimum a Second Class. Regardless of certificate class, the Special Issuance pathway is the same: the FAA evaluates the underlying condition being treated, the stability of the pilot's response to medication, and the absence of disqualifying side effects, before granting authorization. Pilots should expect a more involved initial application but may subsequently be eligible for streamlined renewals once the Special Issuance history is established.
Organizations such as AOPA maintain dedicated medical certification specialists who assist pilots navigating the Special Issuance process at no cost to members, and their guidance is widely regarded as a reliable starting point. The broader aviation safety community has increasingly acknowledged that untreated mental health conditions — not appropriately managed ones — represent the greater threat to flight safety. The FAA's current framework reflects that shift in thinking, aligning regulatory policy with the clinical reality that stable, treated depression or anxiety under approved medications is compatible with safe flight operations. Pilots who proactively disclose and properly document their treatment stand on far stronger legal and professional ground than those who attempt to manage the situation outside the regulatory process.